Exin Therapeutics

AI drug discovery platform for neurotherapeutics

Y CombinatorWinter 2025ActiveHealthcareTherapeuticsNeurotechnologyBiotechTherapeutics

What they do

Problem

Neurological disorders like epilepsy and Parkinson’s lack effective therapeutics that can reliably modify dysfunctional neural activity in the brain.

Solution

An AI-driven drug discovery platform that combines high-throughput multimodal mouse studies with in-house trained models to identify neurotherapeutics that modulate neural activity.

Who it's for

Pharmaceutical and biotech companies developing drugs for neurological disorders.

Founders

Gabriel Ocana Santero

Founder

Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.

LinkedIn · X

Marko Tvrdic

Founder

Cofounder & COO @ Exin Therapeutics. Worked across analysis levels in bio – from molecules to complex behavior. Previously, I worked on retinal and circadian rhythm disorders, neurodevelopment, and systems and comp neuro, with a small stint in venture. Oxford MSc + PhD (on leave to build Exin).

LinkedIn · X